Defining and Treating the Spectrum of Intermediate-Risk NMIBC

Схожие документы

• Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international individual patient data survey (IPDS)
  по: Witjes, J Alfred, et al.
  Опубликовано: (2013)
• Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group
  по: Kamat, Ashish M., et al.
  Опубликовано: (2016)
• Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
  по: Lammers, Rianne J. M., et al.
  Опубликовано: (2015)
• Defining the spectrum of genome policy
  по: Haga, Susanne B., et al.
  Опубликовано: (2006)
• Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-Muscle Invasive Bladder Cancer
  по: Tabayoyong, William B., et al.
  Опубликовано: (2018)